Recombinant Human Soluble Thrombomodulin is Effective for Severe Childhood EBV-HLH

@inproceedings{Kobayashi2016RecombinantHS,
  title={Recombinant Human Soluble Thrombomodulin is Effective for Severe Childhood EBV-HLH},
  author={Chika Kobayashi and Masayuki Nagasawa and Noriko Mitsuiki and Akifumi Endo and Yuki Aoki and Toshiaki Ono and Kohsuke Imai and Masatoshi Takagi and Michiko Kajiwara and Tomohiro Morio},
  year={2016}
}
Hemophagocytic lymphohistiocytosis (HLH) is a fatal disease, presenting with T cell-induced dysregulated cytokine production, systemic inflammation, and frequently intractable coagulopathy. We have administered recombinant human soluble recombinant thrombomodulin (rTM) for four cases of severe childhood Epstein-Barr virus-associated HLH (EBV-HLH) in combination with anti-inflammatory therapy and had good clinical outcomes. To evaluate its efficacy, we retrospectively compared to the former six… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Similar Papers

Loading similar papers…